Literature DB >> 21169473

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.

M C Garassino1, M Marabese2, P Rusconi2, E Rulli3, O Martelli4, G Farina5, A Scanni6, M Broggini2.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21169473     DOI： 10.1093/annonc/mdq680

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  80 in total

1.  The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.

Authors:  Yaxiong Zhang; Wenfeng Fang; Yue Yan; Mengyao Wang; Shiyang Kang; Jin Sheng; Jianhua Zhan; Nan Chen; Shaodong Hong; Yunpeng Yang; Yuxiang Ma; Dacheng He; Tao Qin; Ting Zhou; Yanna Tang; Xiaobo He; Wenhua Liang; Li Zhang
Journal:  Med Oncol       Date:  2015-02-08       Impact factor: 3.064

Review 2.  Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.

Authors:  Jacqueline V Aredo; Sukhmani K Padda
Journal:  Curr Treat Options Oncol       Date:  2018-06-27

Review 3.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

4.  MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer?

Authors:  Stéphane Renaud; Joseph Seitlinger; Gilbert Massard
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

5.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Authors:  Nathan T Ihle; Lauren A Byers; Edward S Kim; Pierre Saintigny; J Jack Lee; George R Blumenschein; Anne Tsao; Suyu Liu; Jill E Larsen; Jing Wang; Lixia Diao; Kevin R Coombes; Lu Chen; Shuxing Zhang; Mena F Abdelmelek; Ximing Tang; Vassiliki Papadimitrakopoulou; John D Minna; Scott M Lippman; Waun K Hong; Roy S Herbst; Ignacio I Wistuba; John V Heymach; Garth Powis
Journal:  J Natl Cancer Inst       Date:  2012-01-13       Impact factor: 13.506

6.  Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Authors:  Timothy F Burns; Hossein Borghaei; Suresh S Ramalingam; Tony S Mok; Solange Peters
Journal:  J Clin Oncol       Date:  2020-10-26       Impact factor: 44.544

Review 7.  Role of genotyping in non-small cell lung cancer treatment: current status.

Authors:  Laura Bonanno; Adolfo Favaretto; Massimo Rugge; Miquel Taron; Rafael Rosell
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

8.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

Review 9.  KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

Authors:  Mónica Garzón; Sergi Villatoro; Cristina Teixidó; Clara Mayo; Alejandro Martínez; Maria de Los Llanos Gil; Santiago Viteri; Daniela Morales-Espinosa; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-10

10.  The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.

Authors:  Anna Biernacka; Peter D Tsongalis; Jason D Peterson; Francine B de Abreu; Candice C Black; Edward J Gutmann; Xiaoying Liu; Laura J Tafe; Christopher I Amos; Gregory J Tsongalis
Journal:  Cancer Genet       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.